- ￥1800 - 3200
- Absin
- abs156055
- 上海
- 2025年08月21日
- WB: 1:1000-2000, IHC-F: 1:50-200, IHC-P: 1:50-200, IF: 1:50-200
- Rabbit
- 见优宁维官网
企业认证
相关产品推荐更多 >
Rabbit anti-WNT11 Polyclonal Antibody【兔抗WNT11多克隆抗体】
询价
CD278/ICOS Recombinant Rabbit mAb (SDT-R104)【CD278/ICOS重组兔单克隆抗体（SDT - R104）】
￥600
Rabbit anti-Histone H3(MonoMethyl-K122) Polyclonal Antibody【兔抗组蛋白H3(单甲基-K122)多克隆抗体】- abs149509
￥1500
Anti-IFNA1 Monoclonal Antibody(Sifalimumab)【抗IFNA1单克隆抗体（西法利姆单抗）】- abs190491
￥1500Rabbit anti-TAAR9 Polyclonal Antibody【兔抗TAAR9多克隆抗体】
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Rabbit anti-VEGFR1 Monoclonal mAb
- 抗体英文名：
Rabbit anti-VEGFR1 Monoclonal Antibody
- 靶点：
见优宁维官网
- 浓度：
1mg/mL
- 应用范围：
WB: 1:1000-2000, IHC-F: 1:50-200, IHC-P: 1:50-200, IF: 1:50-200
- 宿主：
Rabbit
- 适应物种：
见优宁维官网
- 保质期：
见优宁维官网
- 抗原来源：
见优宁维官网
- 级别：
优级
- 库存：
999
- 供应商：
Absin
- 标记物：
Unlabeled
- 克隆性：
3A6
- 保存条件：
Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
- 免疫原：
KLH conjugated synthetic peptide derived from human VEGFR1
- 规格：
100uL/50uL
| 规格： | 100uL | 产品价格： | ￥3200.0 |
|---|---|---|---|
| 规格： | 50uL | 产品价格： | ￥1800.0 |
别名：兔抗VEGFR1单克隆抗体
免疫原：KLH conjugated synthetic peptide derived from human VEGFR1
应用：WB: 1:1000-2000, IHC-F: 1:50-200, IHC-P: 1:50-200, IF: 1:50-200
保持条件：Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
使用方法：WB,IHC-P
标记：Unlabeled
宿主：Rabbit
反应种属：Human,Mouse,
克隆性：3A6
产品描述：见优宁维官网
爱必信品牌介绍：
更多详情请了解优宁维网站》》
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验monoclonal anti-HA 16B12 (MMS101R, BAbCo, used at 1:200 to 1:1000 dilution) mouse monoclonal anti-HA 12CA5 (12CA5, Boehringer, used at 1:200 dilution) rabbit polyclonal anti-HA (RS1010C, BAbCo, used at 1:200 dilution) Cy3-conjugated affinity
until examination. Antibodies mouse monoclonal anti-HA 16B12 (MMS101R, BAbCo, used at 1:200 to 1:1000 dilution) mouse monoclonal anti-HA 12CA5 (12CA5, Boehringer, used at 1:200 dilution) rabbit polyclonal anti-HA (RS1010C, BAbCo, used
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
技术资料暂无技术资料 索取技术资料
